# Haemonetics (HAE): Jumps as CSL plans NexSys devices in all US plasma centers

> Haemonetics rose roughly 14-16% on Oct 8 after CSL said it plans to move all its US plasma centers to Haemonetics' NexSys devices by end-2027, up…

- URL: https://centiview.com/post/haemonetics-hae-jumps-as-csl-plans-nexsys-devices-in-all-us-plasma-centers
- Published: 2026-10-14T03:06:46.000Z
- Sectors: Healthcare
- Region: US
- Ticker: HAE
- Sentiment (opinion, not a recommendation): bullish
- Publisher: Centiview (Persie Ltd, London)
- General information only, not financial advice

Haemonetics rose roughly 14-16% on Oct 8 after CSL said it plans to move all its US plasma centers to Haemonetics' NexSys devices by end-2027, up from 'some' in August. The deal is non-exclusive with no minimum orders, so timing and volume remain open.

> **Why it matters** Growth stalled after CSL's earlier exit: fiscal 2026 organic growth was 1.1%, versus 9.5% excluding CSL disposables sales a year earlier. A full US rollout could rebuild that base, but CSL can still change scope and timing.

> **What we verified** TIKR and MoneyCheck both report the Oct 8, 2026 CSL update, a December 2027 completion target and a share gain of about 14-16%. MoneyCheck adds that the supply agreement has no binding minimums. Management plans to update investors in November.

### Sources
- [TIKR: Haemonetics soars on CSL update, NexSys rollout across US centers](https://www.tikr.com/blog/haemonetics-soars-12-on-csl-update-plasma-giant-to-roll-out-nexsys-across-u-s-centers)
- [MoneyCheck: Haemonetics (HAE) stock jumps as CSL Plasma commits to full US equipment deployment](https://moneycheck.com/haemonetics-hae-stock-jumps-16-as-csl-plasma-commits-to-full-u-s-equipment-deployment/)